Traws Pharma (Traws Pharma) Float Percentage Of Total Shares Outstanding : 82.58% (As of Apr. 28, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Traws Pharma's float shares is 20.89 Mil. Traws Pharma's total shares outstanding is 25.30 Mil. Traws Pharma's float percentage of total shares outstanding is 82.58%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Traws Pharma's Insider Ownership is 3.45%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Traws Pharma's Institutional Ownership is 5.36%.

Traws Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Traws Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	20.89	/	25.30
	=	82.58%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Traws Pharma (Traws Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (NAS:TRAW) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

0T2:Germany

Address

12 Penns Trail, Newtown, PA, USA, 18940

Website

https://www.onconova.com

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Executives

Victor M Moyo	officer: CHIEF MEDICAL OFFICER	12 PENNS TRAIL, NEWTOWN PA 18940
Trafford Clarke	director	12 PENNS TRAIL, NEWTOWN PA 18940
Peter Atadja	director	12 PENNS TRAIL, NEWTOWN PA 18940
Abraham N. Oler	officer: VP Corp Dev & Gen Counsel	C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTERN AVENUE, SUITE 240, HENDERSON NV 89052
Steven M Fruchtman	officer: Chief Medical Officer	375 PHEASANT RUN, NEWTOWN PA 18940
James J Marino	director	C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Gelder Mark S. Md	officer: Chief Medical Officer	C/O A.P. PHARMA, INC., 123 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark Patrick Guerin	officer: Chief Accounting Officer	375 PHEASANT RUN, NEWTOWN PA 18940
Mary Teresa Shoemaker	director	375 PHEASANT RUN, NEWTOWN PA 18940
Michael B Hoffman	director	1 GREENWICH OFFICE PARK, GREENWICH CT 06831
E Premkumar Reddy	director	375 PHEASANT RUN, NEWTOWN PA 18940
Jerome Groopman	director	C/O GENTA INC, TWO CONNELL DR, BERKELEY HEIGHTS NJ 07922
Viren Mehta	director	OSI PHARMACEUTICALS INC, 58 S SERVICE RD STE 110, MELVILLE NY 11747
Tyndall Capital Partners L P	10 percent owner	150 EAST 58TH STREET, 14TH FLOOR, NEW YORK NY 10155
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022